Last edition
News about "off-the-shelf CAR-T therapy"
Allogene Reports ALPHA3 Data: Cema-Cel Shows 58 Percent MRD Clearance in LBCL
Allogene reports ALPHA3 interim data showing 58 percent MRD clearance with cema-cel in LBCL, rapid ctDNA reduction and favourable safety profile with no serious adverse events.
Off-the-shelf CAR-T Therapy | 14/04/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members